LobbyingTaysha Gene Therapies lobbying by quarter
Taysha Gene Therapies TSHA's latest lobbying report covers Q2 2026, at $20K. The four quarters Q4 2025–Q3 2026 total $30K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medicare/Medicaid.
Taysha Gene TherapiesTSHA
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $30K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $10K | 1 |
| Q1 2023 | $10K | 1 |
| Q2 2023 | $10K | 1 |
| Q3 2023 | $0 | 1 |
| Q4 2023 | $0 | 0 |
| Q1 2024 | $0 | 0 |
| Q2 2024 | $0 | 0 |
| Q3 2024 | $0 | 0 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $10K | 1 |
| Q1 2026 | $0 | 1 |
| Q2 2026 | $20K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$15K · 3 reports
- Medicare and Medicaid$15K · 3 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES3 reports
- SENATE3 reports
Firms it paid
| Firm | ||
|---|---|---|
| Acuity Strategic Partners | $30K | 4 quarters |
| Aviva Strategies | $30K | 3 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/17for Q2 | Aviva Strategies | $20K |
| 04/17for Q1 | Aviva Strategies | Under $5,000 |
| 01/15for Q4 2025 | Aviva Strategies | $10K |
| 25/12/11for Q4 2025 | Aviva Strategies | Under $5,000 |
| 23/10/23for Q3 2023 | Acuity Strategic Partners | Under $5,000 |
| 23/07/21for Q2 2023 | Acuity Strategic Partners | $10K |
| 23/04/21for Q1 2023 | Acuity Strategic Partners | $10K |
| 23/01/23for Q4 2022 | Acuity Strategic Partners | $10K |